(ALKS) Alkermes - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 5.794m USD | Total Return: 21.1% in 12m

Schizophrenia, Bipolar, Alcohol, Opioid, Injectable
Total Rating 51
Safety 77
Buy Signal 0.01
Drug Manufacturers - Specialty & Generic
Industry Rotation: -2.3
Market Cap: 5.79B
Avg Turnover: 73.8M USD
ATR: 4.10%
Peers RS (IBD): 32.3
Risk 5d forecast
Volatility39.2%
Rel. Tail Risk-10.9%
Reward TTM
Sharpe Ratio0.46
Alpha-10.77
Character TTM
Beta0.727
Beta Downside1.807
Drawdowns 3y
Max DD31.58%
CAGR/Max DD0.14
EPS (Earnings per Share) EPS (Earnings per Share) of ALKS over the last years for every Quarter: "2021-03": 0.11, "2021-06": 0.3, "2021-09": 0.14, "2021-12": 0.23, "2022-03": 0.12, "2022-06": 0.06, "2022-09": 0.02, "2022-12": 0.14, "2023-03": 0.01, "2023-06": 0.55, "2023-09": 0.64, "2023-12": 0.22, "2024-03": 0.43, "2024-06": 0.7, "2024-09": 0.73, "2024-12": 1.05, "2025-03": 0.13, "2025-06": 0.68, "2025-09": 0.6508, "2025-12": 0.29, "2026-03": 0,
EPS CAGR: -23.01%
EPS Trend: 32.7%
Last SUE: 0.97
Qual. Beats: 1
Revenue Revenue of ALKS over the last years for every Quarter: 2021-03: 251.43, 2021-06: 303.717, 2021-09: 294.141, 2021-12: 324.463, 2022-03: 278.545, 2022-06: 276.219, 2022-09: 252.357, 2022-12: 304.674, 2023-03: 287.595, 2023-06: 617.397, 2023-09: 380.938, 2023-12: 377.475, 2024-03: 350.372, 2024-06: 399.131, 2024-09: 378.143, 2024-12: 429.986, 2025-03: 306.51, 2025-06: 390.657, 2025-09: 394.185, 2025-12: 384.547, 2026-03: null,
Rev. CAGR: 8.98%
Rev. Trend: 48.6%
Last SUE: 0.13
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: ALKS Alkermes

Alkermes plc (NASDAQ: ALKS) is an Ireland-based biopharmaceutical company that discovers, develops, and markets medicines for unmet needs in the United States, Ireland, and other international markets, focusing on neurological and psychiatric disorders.

Its commercial portfolio includes ARISTADA and ARISTADA INITIO for schizophrenia, VIVITROL for alcohol dependence and opioid-use prevention, and the oral antipsychotic LYBALVI, which is in late-stage development for schizophrenia and bipolar I disorder.

In its most recent Q2 2024 earnings release, Alkermes generated $310 million in revenue, held $1.2 billion of cash and marketable securities, and posted a GAAP net loss of $45 million, reflecting ongoing investment in its pipeline and partnership activities with Janssen.

The biotech sector remains a key driver, with U.S. biotech R&D spending projected to rise 7% YoY and AI-enabled drug discovery accelerating timelines-trends that could benefit Alkermes’s technology platforms and pipeline acceleration.

For a deeper dive into how these dynamics translate into valuation metrics, you might explore the latest analysis on ValueRay.

Headlines to Watch Out For
  • VIVITROL sales growth drives revenue expansion
  • RISPERDAL CONSTA patent expiry impacts future earnings
  • Pipeline development success crucial for long-term value
  • Regulatory approvals for new drugs influence stock performance
  • Healthcare policy changes affect prescription drug pricing
Piotroski VR‑10 (Strict) 5.5
Net Income: 241.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.19 > 0.02 and ΔFCF/TA -0.75 > 1.0
NWC/Revenue: 93.89% < 20% (prev 61.00%; Δ 32.89% < -1%)
CFO/TA 0.21 > 3% & CFO 520.8m > Net Income 241.7m
Net Debt (-1.25b) to EBITDA (330.9m): -3.78 < 3
Current Ratio: 3.55 > 1.5 & < 3
Outstanding Shares: last quarter (168.7m) vs 12m ago 1.31% < -2%
Gross Margin: 86.31% > 18% (prev 0.84%; Δ 8.55k% > 0.5%)
Asset Turnover: 64.37% > 50% (prev 75.78%; Δ -11.41% > 0%)
Interest Coverage Ratio: 24.74 > 6 (EBITDA TTM 330.9m / Interest Expense TTM 12.3m)
Altman Z'' 2.45
A: 0.55 (Total Current Assets 1.93b - Total Current Liabilities 543.4m) / Total Assets 2.53b
B: -0.29 (Retained Earnings -734.8m / Total Assets 2.53b)
C: 0.13 (EBIT TTM 303.7m / Avg Total Assets 2.29b)
D: -1.03 (Book Value of Equity -735.1m / Total Liabilities 711.0m)
Altman-Z'' Score: 2.45 = A
Beneish M -3.43
DSRI: 0.91 (Receivables 334.0m/389.5m, Revenue 1.48b/1.56b)
GMI: 0.98 (GM 86.31% / 84.25%)
AQI: 0.75 (AQ_t 0.12 / AQ_t-1 0.16)
SGI: 0.95 (Revenue 1.48b / 1.56b)
TATA: -0.11 (NI 241.7m - CFO 520.8m) / TA 2.53b)
Beneish M-Score: -3.43 (Cap -4..+1) = AA
What is the price of ALKS shares? As of April 13, 2026, the stock is trading at USD 33.36 with a total of 2,005,620 shares traded.
Over the past week, the price has changed by -2.11%, over one month by +20.69%, over three months by +12.63% and over the past year by +21.13%.
Is ALKS a buy, sell or hold? Alkermes has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy ALKS.
  • StrongBuy: 8
  • Buy: 1
  • Hold: 6
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ALKS price?
Analysts Target Price 43.7 31%
Alkermes (ALKS) - Fundamental Data Overview as of 10 April 2026
P/E Trailing = 25.0144
P/E Forward = 151.5152
P/S = 3.926
P/B = 3.1914
P/EG = 1.9605
Revenue TTM = 1.48b USD
EBIT TTM = 303.7m USD
EBITDA TTM = 330.9m USD
Long Term Debt = 70.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.75m USD (from shortTermDebt, last quarter)
Debt = 70.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.25b USD (recalculated: Debt 70.0m - CCE 1.32b)
Enterprise Value = 4.54b USD (5.79b + Debt 70.0m - CCE 1.32b)
Interest Coverage Ratio = 24.74 (Ebit TTM 303.7m / Interest Expense TTM 12.3m)
EV/FCF = 9.46x (Enterprise Value 4.54b / FCF TTM 480.3m)
FCF Yield = 10.57% (FCF TTM 480.3m / Enterprise Value 4.54b)
FCF Margin = 32.55% (FCF TTM 480.3m / Revenue TTM 1.48b)
Net Margin = 16.37% (Net Income TTM 241.7m / Revenue TTM 1.48b)
Gross Margin = 86.31% ((Revenue TTM 1.48b - Cost of Revenue TTM 202.1m) / Revenue TTM)
Gross Margin QoQ = 86.53% (prev 86.91%)
Tobins Q-Ratio = 1.80 (Enterprise Value 4.54b / Total Assets 2.53b)
Interest Expense / Debt = 17.54% (Interest Expense 12.3m / Debt 70.0m)
Taxrate = 18.28% (11.0m / 60.4m)
NOPAT = 248.2m (EBIT 303.7m * (1 - 18.28%))
Current Ratio = 3.55 (Total Current Assets 1.93b / Total Current Liabilities 543.4m)
Debt / Equity = 0.04 (Debt 70.0m / totalStockholderEquity, last quarter 1.82b)
Debt / EBITDA = -3.78 (Net Debt -1.25b / EBITDA 330.9m)
Debt / FCF = -2.60 (Net Debt -1.25b / FCF TTM 480.3m)
Total Stockholder Equity = 1.67b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.54% (Net Income 241.7m / Total Assets 2.53b)
RoE = 14.45% (Net Income TTM 241.7m / Total Stockholder Equity 1.67b)
RoCE = 17.43% (EBIT 303.7m / Capital Employed (Equity 1.67b + L.T.Debt 70.0m))
RoIC = 14.84% (NOPAT 248.2m / Invested Capital 1.67b)
WACC = 8.61% (E(5.79b)/V(5.86b) * Re(8.54%) + D(70.0m)/V(5.86b) * Rd(17.54%) * (1-Tc(0.18)))
Discount Rate = 8.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.41%
[DCF] Terminal Value 79.42% ; FCFF base≈450.5m ; Y1≈547.8m ; Y5≈904.4m
[DCF] Fair Price = 90.75 (EV 13.84b - Net Debt -1.25b = Equity 15.09b / Shares 166.3m; r=8.61% [WACC]; 5y FCF grow 23.10% → 3.0% )
EPS Correlation: 32.71 | EPS CAGR: -23.01% | SUE: 0.97 | # QB: 1
Revenue Correlation: 48.63 | Revenue CAGR: 8.98% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.64 | Chg7d=+0.000 | Chg30d=+0.126 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=2.35 | Chg7d=+0.000 | Chg30d=+0.412 | Revisions Net=+1 | Growth EPS=+12.0% | Growth Revenue=+21.6%
EPS next Year (2027-12-31): EPS=1.99 | Chg7d=-0.078 | Chg30d=-0.408 | Revisions Net=-1 | Growth EPS=-15.2% | Growth Revenue=+4.6%
External Resources
Dataroma Stockcircle